依达拉奉辅助治疗重症颅脑损伤的效果观察
|
摘要
目的探讨依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者的效果。方法选取我院2014年1月至2018年7月收治的重症颅脑损伤患者352例,随机分为联合组和对照组,各176例。联合组给予依达拉奉联合脑苷肌肽治疗,对照组给予脑苷肌肽治疗。观察两组患者治疗前后的GCS评分、 ICP、颅脑损伤标记物(S-100B、 GFAP、 NSE、 UCH-L1)水平及不良反应情况。结果治疗后,两组患者的GCS评分显著高于治疗前,且联合组的GCS评分显著高于对照组(P均<0.05)。治疗后,两组患者的ICP、颅脑损伤标记物水平显著低于治疗前,且联合组的ICP、颅脑损伤标记物水平显著低于对照组(P均<0.05)。两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论依达拉奉联合脑苷肌肽治疗重症颅脑损伤可显著提高患者的GCS评分,降低ICP,改善颅脑损伤,且安全性好,值得推广应用。
Objective To explore the effect of edaravone combined with cerebroside carnosine in the treatment of patients with severe craniocerebral injury. Methods 352 cases of patients with severe craniocerebral injury admitted to our hospital from January 2014 to July 2018 were selected and randomly divided into combined group and control group, with 176 cases in each group. The combined group was treated with edaravone combined with cerebroside carnosine, while the control group was treated with cerebroside carnosine. The GCS scores, ICP and levels of craniocerebral injury markers(S-100 B, GFAP, NSE, UCH-L1) before and after treatment, and adverse reactions of the two groups were observed. Restults After treatment, the GCS scores of two groups were significantly higher than those before treatment,and the GCS score of the combined group was significantly higher than that of the control group(all P <0.05). After treatment, the ICP and levels of craniocerebral injury markers of two groups were significantly lower than those before treatment, and the ICP and levels of craniocerebral injury markers of the combined group were significantly lower than those of the control group(all P <0.05). No statistical diffference was found in the incidence of adverse reactions between the two groups(P >0.05). Conclusions Edaravone combined with cerebroside carnosine in the treatment of severe craniocerebral injury can significantly improve patients' GCS score, reduce the ICP, and improve the brain injury with good safety, which is worthy of promotion and application.
Objective To explore the effect of edaravone combined with cerebroside carnosine in the treatment of patients with severe craniocerebral injury. Methods 352 cases of patients with severe craniocerebral injury admitted to our hospital from January 2014 to July 2018 were selected and randomly divided into combined group and control group, with 176 cases in each group. The combined group was treated with edaravone combined with cerebroside carnosine, while the control group was treated with cerebroside carnosine. The GCS scores, ICP and levels of craniocerebral injury markers(S-100 B, GFAP, NSE, UCH-L1) before and after treatment, and adverse reactions of the two groups were observed. Restults After treatment, the GCS scores of two groups were significantly higher than those before treatment,and the GCS score of the combined group was significantly higher than that of the control group(all P <0.05). After treatment, the ICP and levels of craniocerebral injury markers of two groups were significantly lower than those before treatment, and the ICP and levels of craniocerebral injury markers of the combined group were significantly lower than those of the control group(all P <0.05). No statistical diffference was found in the incidence of adverse reactions between the two groups(P >0.05). Conclusions Edaravone combined with cerebroside carnosine in the treatment of severe craniocerebral injury can significantly improve patients' GCS score, reduce the ICP, and improve the brain injury with good safety, which is worthy of promotion and application.
引文
[1]李明.神经节苷酯钠辅助治疗对急性重症颅脑损伤患者神经损伤程度及细胞因子、体液免疫的影响[J].海南医学院学报, 2017,23(1):48-51.
[2]吴毅.重症颅脑损伤后意识障碍的精准康复[J].中国康复医学杂志, 2017, 32(3):249-252.
[3]王龙珍,薛胜详.脑苷肌肽联合侬达拉奉对重症颅脑损伤的临床疗效[J].西南国防医药, 2017, 27(8):858-860.
[4]陆斌,陈思.脑苷肌肽注射液联合鼠神经生长因子注射剂治疗重症颅脑损伤的临床研究[J].中国临床药理学杂志, 2017, 33(15):1397-1399.
[5]缪一艇,童凌云,王勇,等.神经生长因子对重型颅脑损伤患者的治疗效果及血清MMP-2、 NSE影响研究[J].中华全科医学, 2016,14(12):2040-2041, 2066.
[6]周婷,张平,张莉,等.神经节苷酯钠治疗急性重症颅脑损伤的临床疗效研究[J].中国临床药理学杂志, 2016, 32(7):582-584.
[7]张岩,张丽,徐如祥.依达拉奉给药途径及治疗急性脑梗死的研究进展[J/CD].中华神经创伤外科杂志(电子版), 2017, 3(1):44-47.
[8]陈奇翰,林丹,邓钢,等.依达拉奉联合脑苷肌肽治疗重症颅脑损伤的临床研究[J].中国临床药理学杂志, 2016, 32(14):1261-1264.
[2]吴毅.重症颅脑损伤后意识障碍的精准康复[J].中国康复医学杂志, 2017, 32(3):249-252.
[3]王龙珍,薛胜详.脑苷肌肽联合侬达拉奉对重症颅脑损伤的临床疗效[J].西南国防医药, 2017, 27(8):858-860.
[4]陆斌,陈思.脑苷肌肽注射液联合鼠神经生长因子注射剂治疗重症颅脑损伤的临床研究[J].中国临床药理学杂志, 2017, 33(15):1397-1399.
[5]缪一艇,童凌云,王勇,等.神经生长因子对重型颅脑损伤患者的治疗效果及血清MMP-2、 NSE影响研究[J].中华全科医学, 2016,14(12):2040-2041, 2066.
[6]周婷,张平,张莉,等.神经节苷酯钠治疗急性重症颅脑损伤的临床疗效研究[J].中国临床药理学杂志, 2016, 32(7):582-584.
[7]张岩,张丽,徐如祥.依达拉奉给药途径及治疗急性脑梗死的研究进展[J/CD].中华神经创伤外科杂志(电子版), 2017, 3(1):44-47.
[8]陈奇翰,林丹,邓钢,等.依达拉奉联合脑苷肌肽治疗重症颅脑损伤的临床研究[J].中国临床药理学杂志, 2016, 32(14):1261-1264.